Aethon Therapeutics’ Post

🔬Angle Partners with AstraZeneca to Develop Advanced Cancer Assay🔬https://lnkd.in/eHPazZgk ANGLE and AstraZeneca are collaborating to customize Angle's Parsortix-based DNA damage response (DDR) assay for use in pharmaceutical R&D. The partnership aims to develop a novel methodology for detecting micronuclei in circulating tumor cells, which could support the development of targeted cancer therapies and monitor treatment response. #CancerResearch #LiquidBiopsy #PrecisionMedicine #DrugDevelopment

Exciting trial results for lung cancer patients! A recent Phase 3 clinical trial presented at the World Conference on Lung Cancer showed that Summit Therapeutics' experimental drug, ivonescimab, outperformed Merck & Co.'s Keytruda in treating advanced non-small cell lung cancer. The results indicate that ivonescimab cut the risk of lung cancer progression or death by 49% compared to Keytruda, with a median progression-free survival of 11 months, compared to 6 months for Keytruda, demonstrating a statistically significant 5.3-month difference. Doctors described the findings as "striking" and "impressive," suggesting that ivonescimab could become a new standard treatment for lung cancer patients if further testing confirms its benefit. Read more here: https://loom.ly/_fjEQ_E #lungcancer #cancerpatient #therapeutics #results #researchcompliance

I am delighted to share the announcement of a #collaboration that I have initiated and will be leading on behalf of my client OregonTherapeutics trough my service Lab2BIOTECH. This collaboration involves the analysis of the #preclinical package of Oregon Therapeutics' lead product, XCE853, by Lantern Pharma Inc. (Nasdaq: LTRN) Pharma's #AI based RADR® platform, in order to identify the best clinical positioning of this #drug candidate for #Cancer patient's and further progress toward clinics together.  Please see the press release below. --- Personal notes: This is AI as I like it: no buzzwords, concrete analysis of huge datasets and literature points to leverage smarter strategies in #drugdevelopment and improve patient's impact. This collaboration is also a good illustration of my vision on how best to develop assets for startups. Licensing a drug candidate is not a final step at the end of a development plan. It's an ongoing process, starting from day one of project management, and requires open-mindedness, seeking out opportunities and collaborating with potential licensees to build trust and improve product-market fit with payers' expectations, while driving R&D forward.  Tip for founders: surround yourself!

Cancer treatment is evolving, and at Immunai we're excited to play a key role in shaping its future. Immunai's new multi-year collaboration with AstraZeneca a aims to advance oncology clinical trials by leveraging our AI platforms, AMICA™, and the Immunodynamics Engine (IDE)™. We’re working together to gain deeper insights into patient responses, optimize dose selection, and identify key biomarkers for cancer treatment. Learn more about the collaboration from https://lnkd.in/dQNZ-u9e

Last month, Altamira Therapeutics filed a second provisional patent application for OligoPhore™ nanoparticles targeting different #KRAS mutations in cancer treatment. Although the role of KRAS mutations in cancer has been known for decades, they have remained a challenging target for therapeutic interventions. KRAS was long considered undruggable, in part, because of the lack of obvious binding sites. Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC. We look forward to advancing our AM-401 program to provide clinicians and patients with a comprehensive treatment option for KRAS-driven cancers: https://bit.ly/3HwrVmw #Science #RNATherapeutics #siRNA #mRNA

We are excited to share our latest review article in Biomedicines: "Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment." 🚀 In this paper, we dive deep into the complexities of cancer drug resistance—a significant challenge in oncology—and explore cutting-edge strategies to combat it. From targeted protein degradation to novel immunotherapy combinations and precision medicine, we highlight innovative approaches that promise to transform cancer treatment and improve patient outcomes. Check out the full article here: https://lnkd.in/eSHNqFpB Mario DiPaola; MDPI #CancerResearch #Oncology #PrecisionMedicine #DrugResistance #CancerTreatment #Immunotherapy #Biomedicine #Therabene

What promises ADCs can bring? Find out more in #Biocompare where Namrata Jayanth shares her view on it's promises for Cancer treatments. "ADCs represent a transformative approach to targeted cancer therapy, offering the potential for more effective, less toxic treatments. As the field continues to evolve, advances in ADC design, targeting strategies, and combination therapies are expected to enhance ADC effectiveness and broaden their clinical application.” Discovery | Charles River #ADC #Oncology #drugdiscovery https://lnkd.in/d9zED6gj.

🚀 2024 has been a year of therapeutic breakthroughs for endometrial cancer, the sixth most common cancer in women. 📈 This year has seen a number of checkpoint inhibitors receive regulatory approval to treat the disease. ADC drugs in clinical trials are also turning heads. 🏥 Labiotech spoke to Music Beats Cancer’s founder Mona Jhaveri and Joshua Garrett Cohen from City of Hope in the U.S. about these advancements. ✅ Read our latest article to find out about these recent drug approvals and some up-and-coming candidates in the clinic! 👇 https://lnkd.in/dNuCcEjN #endometrialcancer #therapeuticbreakthroughs #ADCtherapies #cancerresearch #biotechnews GSK | AstraZeneca | Merck | Daiichi Sankyo | ImmunoGen, Inc. | BioNTech SE

Elicio Therapeutics, a clinical-stage biotech firm, unveiled encouraging preliminary data from its AMPLIFY-7P Phase 1a study of ELI-002 7P, an investigational cancer vaccine targeting mKRAS-driven solid tumors. The study found ELI-002 7P was well-tolerated and generated robust T cell responses against multiple KRAS mutations, correlating with reduced tumor biomarkers at the recommended Phase 2 dose. 'These early immunogenicity and biomarker response data from ELI-002 7P continue to provide encouraging results showing that our lymph node-targeted approach generates a robust and differentiated T cell response that strongly correlates with tumor biomarker reductions,' said Christopher Haqq, MD, PhD, executive vice president and head of R&D at @eliciotherapeutics. The findings demonstrated ELI-002 7P's potential to address the high unmet need in treating KRAS-mutated tumors, which account for 25% of solid tumors and have limited treatment options. The data was presented at the prestigious @asco Annual Meeting. #biotechnology #oncology #clinicaltrial #immunotherapy #kras

🌟 Major Step Forward in Cancer Treatment: Angiex has officially dosed the first patient in its Phase 1 trial of a novel ADC (antibody-drug conjugate) therapy. 💉 This trial marks an important milestone in the development of targeted cancer therapies, potentially offering a new lifeline for patients facing tough-to-treat cancers. As Angiex continues to advance this promising therapy, the biopharma industry is watching closely. 🔍 #ClinicalTrials #CancerTreatment #ADCTherapy #Biopharma #OncologyInnovation 🔗 Explore the details of this exciting trial and its potential impact on cancer care: https://lnkd.in/e5JSkJHA